



## The FDA Safety Information and Adverse Event Reporting Program

### **Olmesartan (Benicar)**

[06/11/2010]

根據一項流行病學研究，觀察發現常用於治療高血壓的血管張力素受體阻斷劑（angiotensin-receptor blocker，ARB），比沒有使用該類藥品的病人，被診斷出有新的癌症的機率較高，但就現有資料無法確認其關聯性，ARB 類藥品尚無安全疑慮。另外美國FDA 根據二個正在進行的臨床試驗（ROADMAP 和ORIENT）發現，罹患第二型糖尿病患者，使用ARB 類的olmesartan 成分藥品（藥品名稱：Benicar）可能增加心臟血管方面的風險，甚至死亡。但其關聯性也尚未確認。

### **Olmesartan (Benicar)**

**Audience:** Cardiology, Internal Medicine

[Posted 06/11/2010]

FDA is evaluating data from two clinical trials in which patients with type 2 diabetes taking the blood pressure medication, Benicar (olmesartan), an angiotensin II receptor blocker, had a higher rate of death from a cardiovascular cause compared to patients taking a placebo. FDA's review is ongoing and the Agency has not concluded that Benicar increases the risk of death. FDA currently believes that the benefits of Benicar in patients with high blood pressure continue to outweigh its potential risks.